661 related articles for article (PubMed ID: 12391943)
21. Cholinesterase inhibitors in the clinical management of Alzheimer's disease: importance of early and persistent treatment.
Seltzer B
J Int Med Res; 2006; 34(4):339-47. PubMed ID: 16989488
[TBL] [Abstract][Full Text] [Related]
22. [Retrospective comparative analysis of antidementia medication persistence patterns in Spanish Alzheimer's disease patients treated with donepezil, rivastigmine, galantamine and memantine].
Sicras-Mainar A; Vergara J; Leon-Colombo T; Febrer L; Rejas-Gutierrez J
Rev Neurol; 2006 Oct 16-31; 43(8):449-53. PubMed ID: 17033976
[TBL] [Abstract][Full Text] [Related]
23. Impact of rivastigmine on costs and on time spent in caregiving for families of patients with Alzheimer's disease.
Marin D; Amaya K; Casciano R; Puder KL; Casciano J; Chang S; Snyder EH; Cheng I; Cuccia AJ
Int Psychogeriatr; 2003 Dec; 15(4):385-98. PubMed ID: 15000418
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
Neumann PJ; Hermann RC; Kuntz KM; Araki SS; Duff SB; Leon J; Berenbaum PA; Goldman PA; Williams LW; Weinstein MC
Neurology; 1999 Apr; 52(6):1138-45. PubMed ID: 10214734
[TBL] [Abstract][Full Text] [Related]
25. Comparative Effectiveness and Safety of Cognitive Enhancers for Treating Alzheimer's Disease: Systematic Review and Network Metaanalysis.
Tricco AC; Ashoor HM; Soobiah C; Rios P; Veroniki AA; Hamid JS; Ivory JD; Khan PA; Yazdi F; Ghassemi M; Blondal E; Ho JM; Ng CH; Hemmelgarn B; Majumdar SR; Perrier L; Straus SE
J Am Geriatr Soc; 2018 Jan; 66(1):170-178. PubMed ID: 29131306
[TBL] [Abstract][Full Text] [Related]
26. An open-label, comparative study of rivastigmine, donepezil and galantamine in a real-world setting.
Aguglia E; Onor ML; Saina M; Maso E
Curr Med Res Opin; 2004 Nov; 20(11):1747-52. PubMed ID: 15537474
[TBL] [Abstract][Full Text] [Related]
27. Cost effectiveness of donepezil in the treatment of mild to moderate Alzheimer's disease: a UK evaluation using discrete-event simulation.
Getsios D; Blume S; Ishak KJ; Maclaine GD
Pharmacoeconomics; 2010; 28(5):411-27. PubMed ID: 20402542
[TBL] [Abstract][Full Text] [Related]
28. Savings in the cost of caring for patients with Alzheimer's disease in Canada: an analysis of treatment with rivastigmine.
Hauber AB; Gnanasakthy A; Mauskopf JA
Clin Ther; 2000 Apr; 22(4):439-51. PubMed ID: 10823365
[TBL] [Abstract][Full Text] [Related]
29. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence.
Lockhart IA; Mitchell SA; Kelly S
Dement Geriatr Cogn Disord; 2009; 28(5):389-403. PubMed ID: 19893314
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and safety of rivastigmine in patients with Alzheimer's disease who failed to benefit from treatment with donepezil.
Auriacombe S; Pere JJ; Loria-Kanza Y; Vellas B
Curr Med Res Opin; 2002; 18(3):129-38. PubMed ID: 12094822
[TBL] [Abstract][Full Text] [Related]
31. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
Chianella C; Gragnaniello D; Maisano Delser P; Visentini MF; Sette E; Tola MR; Barbujani G; Fuselli S
Eur J Clin Pharmacol; 2011 Nov; 67(11):1147-57. PubMed ID: 21630031
[TBL] [Abstract][Full Text] [Related]
32. Economic evaluation of donepezil for the treatment of Alzheimer's disease in Canada.
O'Brien BJ; Goeree R; Hux M; Iskedjian M; Blackhouse G; Gagnon M; Gauthier S
J Am Geriatr Soc; 1999 May; 47(5):570-8. PubMed ID: 10323651
[TBL] [Abstract][Full Text] [Related]
33. Use of cholinesterase inhibitors for treatment of Alzheimer disease.
Hake AM
Cleve Clin J Med; 2001 Jul; 68(7):608-9, 613-4, 616. PubMed ID: 11453078
[TBL] [Abstract][Full Text] [Related]
34. Maintaining functional and behavioral abilities in Alzheimer disease.
Winblad B
Alzheimer Dis Assoc Disord; 2001 Aug; 15 Suppl 1():S34-40. PubMed ID: 11669508
[TBL] [Abstract][Full Text] [Related]
35. Current treatments for Alzheimer's disease: cholinesterase inhibitors.
Doody RS
J Clin Psychiatry; 2003; 64 Suppl 9():11-7. PubMed ID: 12934969
[TBL] [Abstract][Full Text] [Related]
36. A meta-analysis of the efficacy of donepezil, rivastigmine, galantamine, and memantine in relation to severity of Alzheimer's disease.
Di Santo SG; Prinelli F; Adorni F; Caltagirone C; Musicco M
J Alzheimers Dis; 2013; 35(2):349-61. PubMed ID: 23411693
[TBL] [Abstract][Full Text] [Related]
37. Differential efficacy of treatment with acetylcholinesterase inhibitors in patients with mild and moderate Alzheimer's disease over a 6-month period.
López-Pousa S; Turon-Estrada A; Garre-Olmo J; Pericot-Nierga I; Lozano-Gallego M; Vilalta-Franch M; Hernández-Ferràndiz M; Morante-Muñoz V; Isern-Vila A; Gelada-Batlle E; Majó-Llopart J
Dement Geriatr Cogn Disord; 2005; 19(4):189-95. PubMed ID: 15677866
[TBL] [Abstract][Full Text] [Related]
38. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
Sharma JC
Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537
[No Abstract] [Full Text] [Related]
39. Effectiveness of cholinesterase inhibitors and memantine for treating dementia: evidence review for a clinical practice guideline.
Raina P; Santaguida P; Ismaila A; Patterson C; Cowan D; Levine M; Booker L; Oremus M
Ann Intern Med; 2008 Mar; 148(5):379-97. PubMed ID: 18316756
[TBL] [Abstract][Full Text] [Related]
40. Switching cholinesterase inhibitor therapy in Alzheimer's disease--donepezil to rivastigmine, is it worth it?
Bullock R; Connolly C
Int J Geriatr Psychiatry; 2002 Mar; 17(3):288-9. PubMed ID: 11921158
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
